Condensed Ring Compounds for D3/D2-Selective Antagonism

The patent applies local quality by introducing specific substituent patterns at defined positions on the aromatic ring system. By controlling the nature and position of substituents (R1-R6) on the condensed ring structure, the compound achieves selective interaction with D3 receptor over D2 receptor, thereby improving selectivity while maintaining antagonistic activity and reducing off-target side effects.

The patent employs parameter changes by systematically varying the chemical structure parameters of the compounds, including the type of heteroatoms in the condensed ring system, the nature of substituent groups (R1-R6), and their positions. These structural parameter modifications enable fine-tuning of receptor binding affinity and selectivity, achieving high D3/D2 selectivity ratios while preserving potent D3 antagonistic activity.

The patent utilizes parameter changes by optimizing the chemical structure parameters of the compounds. By modifying the condensed ring core structure (aromatic heterocycles with specific heteroatom arrangements) and adjusting substituent parameters (R1-R6 groups including alkyl, alkoxy, halogen, and aromatic substituents), the invention achieves compounds with both potent D3 receptor antagonistic activity and high D3/D2 selectivity, thereby maximizing therapeutic benefit for D3-mediated disorders.

The patent applies composite materials by creating compounds with a composite molecular structure consisting of a condensed ring core system fused with aromatic heterocyclic rings, combined with various substituent groups. This composite structural approach enables simultaneous optimization of multiple properties: high D3 receptor binding affinity, high D3/D2 selectivity, and favorable pharmacokinetic properties, leading to effective therapeutic agents.